{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:17:11Z","timestamp":1771539431995,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd010774","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T00:00:00Z","timestamp":1431993600000}}],"reference-count":65,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010774.pub2","type":"journal-article","created":{"date-parts":[[2015,5,19]],"date-time":"2015-05-19T22:36:22Z","timestamp":1432074982000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rapid COJEC versus standard induction therapies for high-risk neuroblastoma"],"prefix":"10.1002","volume":"2016","author":[{"given":"Frank","family":"Peinemann","sequence":"first","affiliation":[{"name":"University of Cologne; Children's Hospital; Kerpener Str. 62 Cologne NW Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen A","family":"Kahangire","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham and Black Country NIHR CLAHRC; School of Health and population, Public Health Building College of Medical and Dental Sciences Birmingham West Midlands UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 (room H4-139) Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Berthold","sequence":"additional","affiliation":[{"name":"Children's Hospital, University of Cologne; Pediatric Oncology and Hematology; Kerpener Strasse 62 Cologne Germany 50937"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,19]]},"reference":[{"key":"10.1002\/14651858.CD010774.pub2-BIB0001|cit1","unstructured":"Moreno L Vaidya S Pinkerton R Lewis IJ Imeson J Ellershaw C Abstract PL36. Long-term toxicity in survivors of ENSG5 trial for children with high risk neuroblastoma The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden Stockholm Advances in Neuroblastoma Research Association (ANRA) 2010 105"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0002|cit2","unstructured":"Moreno L Vaidya S Pinkerton R Lewis IJ Imeson J Ellershaw C Abstract SEL10. Persistence of disease in long-term survivors of high-risk neuroblastoma. Analysis of ENSG5 cooperative trial The Advances in Neuroblastoma Research 2010 conference, 21 to 24 June 2010 in Stockholm, Sweden Stockholm Advances in Neuroblastoma Research Association (ANRA) 2010 136"},{"issue":"7","key":"10.1002\/14651858.CD010774.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/pbc.24452","article-title":"Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience","volume":"60","author":"Moreno","year":"2013","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010774.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Pearson","year":"2008","journal-title":"Lancet Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010774.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/08880018.2010.526684","article-title":"Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival","volume":"28","author":"Bomken","year":"2011","journal-title":"Pediatric Hematology and Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1517\/14656566.5.1.71","article-title":"A comparison of current neuroblastoma chemotherapeutics","volume":"5","author":"Castel","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"8","key":"10.1002\/14651858.CD010774.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2003.05.191","article-title":"Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma","volume":"21","author":"Bernardi","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.4081\/oncol.2012.e3","article-title":"Management of neuroblastoma: A study of first- and second-line chemotherapy responses, a single institution experience","volume":"6","author":"Habib","year":"2012","journal-title":"Oncology Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010774.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-2008-1043950","article-title":"Does megatherapy contribute to survival in metastatic neuroblastoma? A retrospective analysis. German Cooperative Neuroblastoma Study Group","volume":"209","author":"Hero","year":"1997","journal-title":"Klinische P\u00e4diatrie"},{"issue":"S6","key":"10.1002\/14651858.CD010774.pub2-BIB0010|cit10","first-page":"400","article-title":"Children with high-risk neuroblastoma may be long-term survivors after application of intensified multimodal therapy. SIOP 2004 meeting abstracts: P.C.005","volume":"43","author":"Kogner","year":"2004","journal-title":"Pediatric Blood and Cancer"},{"issue":"S6","key":"10.1002\/14651858.CD010774.pub2-BIB0011|cit11","first-page":"402","article-title":"The SIOPEN-R-NET project: Building a European network for neuroblastoma treatment (HR-NBL-1\/ESIOP trial) and research. SIOP 2004 meeting abstract: P.C.014","volume":"43","author":"Ladenstein","year":"2004","journal-title":"Pediatric Blood and Cancer"},{"issue":"21","key":"10.1002\/14651858.CD010774.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1200\/JCO.2009.27.3524","article-title":"Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1\/SIOPEN study","volume":"28","author":"Ladenstein","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD010774.pub2-BIB0013|cit13","first-page":"732","article-title":"The prognostic value of semi-quantitative I-123 MIBG scintigraphy at diagnosis in high risk neuroblastoma: Validation of the siopen score method. SIOP 2011 meeting abstract: O102","volume":"57","author":"Ladenstein","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0959-8049(11)70317-3","article-title":"Recent advancements for high risk neuroblastoma (HRN) in Europe through the siop Europe neuroblastoma group (SIOPEN). European Multidisciplinary Cancer Congress 2011 meeting abstract: 102","volume":"47 Suppl 1","author":"Ladenstein","year":"2011","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD010774.pub2-BIB0015|cit15","first-page":"733","article-title":"Busulphan-melphalan is the superior myeloablative therapy (MAT) for high risk neuroblastoma: Results from the HR-NBL1\/siopen trial. SIOP 2011 meeting abstract: O103","volume":"57","author":"Ladenstein","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"issue":"6","key":"10.1002\/14651858.CD010774.pub2-BIB0016|cit16","first-page":"988","article-title":"Major results from the HR-NBl1\/siopen trial for high risk neuroblastoma. SIOP 2012 meeting abstract: O069","volume":"59","author":"Ladenstein","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0017|cit17","unstructured":"Ladenstein R Potschger U Lewington V Bar-Sever Z Lambert B Oudoux A Update on the prognostic value of the SIOPEN skeletal scoring method in the high-risk stage 4 neuroblastoma by semi-quantitative I-123-mIBG scintigraphy. OGKJ 2012 meeting abstract Monatsschrift fur Kinderheilkunde 2012 271"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Lewington V Poetschger U Boubaker A Bar-Sever Z Drake B Staudenherz A The prognostic value of semi-quantitative 123I mIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method [9511] ASCO 2011 Annual Meeting; Journal of Clinical Oncology 2011 http:\/\/meetinglibrary.asco.org\/content\/83036 102","DOI":"10.1200\/jco.2011.29.15_suppl.9511"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/pbc.22986","article-title":"Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen","volume":"56","author":"Mastrangelo","year":"2011","journal-title":"Pediatric Blood and Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010774.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mpo.2950080310","article-title":"Intensive chemotherapy for metastatic neuroblastoma: a Southwest Oncology Group study","volume":"8","author":"Nitschke","year":"1980","journal-title":"Medical and Pediatric Oncology"},{"issue":"14","key":"10.1002\/14651858.CD010774.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/S0959-8049(00)00189-1","article-title":"Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC)","volume":"36","author":"Pinkerton","year":"2000","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L","article-title":"Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan","volume":"66","author":"Sawaguchi","year":"1990","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0023|cit23","unstructured":"Schrey D Vaidya S Levine D Moreno L Pearson A Inadequate response to induction chemotherapy in children with high-risk neuroblastoma: An institutional analysis [P-0244] 45th Congress of The International Society of Paediatric Oncology (SIOP), Hong Kong; Pediatric Blood and Cancer 2013 111"},{"issue":"7","key":"10.1002\/14651858.CD010774.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.1984.2.7.742","article-title":"Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26","volume":"2","author":"Shafford","year":"1984","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/1096-911X(20010101)36:1<239::AID-MPO1058>3.0.CO;2-G","article-title":"OPEC\/OJEC for stage 4 neuroblastoma in children over 1 year of age","volume":"36","author":"Tweddle","year":"2001","journal-title":"Medical and Pediatric Oncology"},{"issue":"6","key":"10.1002\/14651858.CD010774.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/pbc.24713","article-title":"Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy","volume":"61","author":"Valteau-Couanet","year":"2014","journal-title":"Pediatric Blood and Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010774.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.2013.53.3604","article-title":"Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1\/SIOPEN study","volume":"32","author":"Viprey","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0028|cit28","unstructured":"Ladenstein A High Risk Neuroblastoma Study 1 (1.5) of SIOP-Europe (SIOPEN) ClinicalTrials.gov; ID: NCT01704716; URL: http:\/\/clinicaltrials.gov\/show\/NCT01704716"},{"issue":"9","key":"10.1002\/14651858.CD010774.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(05)70291-6","article-title":"Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial","volume":"6","author":"Berthold","year":"2005","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1148\/radiol.11101352","article-title":"Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project","volume":"261","author":"Brisse","year":"2011","journal-title":"Radiology"},{"issue":"4","key":"10.1002\/14651858.CD010774.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"295-300","DOI":"10.1002\/mpo.2950190415","article-title":"Cisplatin ototoxicity in children: A practical grading system","volume":"19","author":"Brock","year":"1991","journal-title":"Medical and Pediatric Oncology"},{"issue":"8","key":"10.1002\/14651858.CD010774.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U","article-title":"N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age","volume":"36","author":"Cheung","year":"2001","journal-title":"Medical and Pediatric Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0034|cit34","unstructured":"NIH National Institutes of Health ClinicalTrials.gov http:\/\/clinicaltrials.gov\/"},{"issue":"2","key":"10.1002\/14651858.CD010774.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report","volume":"27","author":"Cohn","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD010774.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1158\/1078-0432.CCR-11-1409","article-title":"New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome","volume":"18","author":"Cole","year":"2012","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD010774.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0038|cit38","unstructured":"Thomson Reuters EndNote 2014"},{"issue":"1","key":"10.1002\/14651858.CD010774.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pbc.20859","article-title":"Neuroblastoma in adults: incidence and survival analysis based on SEER data","volume":"49","author":"Esiashvili","year":"2007","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0040|cit40","unstructured":"Genetic and Rare Diseases Information Center (GARD) The Office of Rare Diseases Research (ORDR) Neuroblastoma http:\/\/rarediseases.info.nih.gov\/GARD\/Condition\/7185\/Neuroblastoma.aspx"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0041|cit41","unstructured":"Goodman MT Gurney JG Smith MA Olshan AF SEER Pediatric Monograph. Sympathetic Nervous System Tumors http:\/\/seer.cancer.gov\/publications\/childhood\/sympathetic.pdf"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0042|cit42","unstructured":"Gesellschaft f\u00fcr P\u00e4diatrische Onkologie und H\u00e4matologie NB2004 trial protocol for risk adapted treatment of children with neuroblastoma http:\/\/www.kinderkrebsinfo.de\/sites\/kinderkrebsinfo\/content\/e1676\/e9032\/e1758\/e7671\/download7673\/NB_2004_1.00_komprimiert__ger.pdf 2004"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0043|cit43","unstructured":"Information Management System (IMS), The Nordic Cochrane Centre, The Cochrane Collaboration GRADEpro (GRADE profiler) 2008"},{"issue":"9","key":"10.1002\/14651858.CD010774.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.2007.12.3349","article-title":"Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97","volume":"26","author":"Hero","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0046|cit46","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0047|cit47","unstructured":"International Clinical Studies Support Center (ICSSC) WHO Toxicity Grading Scale for Determining The Severity of Adverse Events http:\/\/www.icssc.org\/Documents\/Resources\/AEManual2003AppendicesFebruary_06_2003%20final.pdf"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0048|cit48","unstructured":"ICTRP International Clinical Trials Registry Platform WHO World Health Organization ICTRP Search Platform http:\/\/apps.who.int\/trialsearch\/"},{"issue":"10","key":"10.1002\/14651858.CD010774.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0050|cit50","unstructured":"Kremer LCM van Dalen EC Moher D Caron HN Cochrane Childhood Cancer Group About The Cochrane Collaboration 2008, Issue 3. Art. No.: CHILDCA"},{"issue":"12","key":"10.1002\/14651858.CD010774.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.1994.12.12.2607","article-title":"Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age","volume":"12","author":"Kushner","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD010774.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1200\/JCO.2004.02.101","article-title":"Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma","volume":"22","author":"Kushner","year":"2004","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0053|cit53","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"16","key":"10.1002\/14651858.CD010774.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010774.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0057|cit57","unstructured":"National Cancer Institute (NCI) Bethesda MD USA Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0058|cit58","unstructured":"National Cancer Institute (NCI) at the National Institutes of Health (NIH) Physician Data Query (PDQ) Neuroblastoma treatment http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/neuroblastoma\/HealthProfessional"},{"issue":"33","key":"10.1002\/14651858.CD010774.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study","volume":"29","author":"Park","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD010774.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010774.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(08)70069-X","article-title":"High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial","volume":"9","author":"Pearson","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0062|cit62","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2013"},{"key":"10.1002\/14651858.CD010774.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"8","key":"10.1002\/14651858.CD010774.pub2-BIB0064|cit64","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006301.pub3","article-title":"High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma","author":"Yalcin","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD010774.pub2-BIB0065|cit65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010774","article-title":"Rapid COJEC versus standard induction therapies for high-risk neuroblastoma","author":"Peinemann","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010774.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:47:31Z","timestamp":1694713651000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010774.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,19]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010774.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,19]]}}}